Progress toward molecular therapy for diabetes mellitus: A focus on targeting inflammatory factors

Mohadesse Dehghan; Fateme Ghorbani; Sajad Najafi; Neda Ravaei; Maede Karimian; Kambiz Kalhor; Abolfazl Movafagh; Seyed Mohsen Aghaei Zarch

doi:10.1016/j.diabres.2022.109945

Progress toward molecular therapy for diabetes mellitus: A focus on targeting inflammatory factors

Diabetes Res Clin Pract. 2022 Jul:189:109945. doi: 10.1016/j.diabres.2022.109945. Epub 2022 Jun 9.

Authors

Mohadesse Dehghan¹, Fateme Ghorbani², Sajad Najafi³, Neda Ravaei⁴, Maede Karimian⁵, Kambiz Kalhor⁶, Abolfazl Movafagh⁷, Seyed Mohsen Aghaei Zarch⁸

Affiliations

¹ Department of Microbiology, Faculity of Life Science, Islamic Azad University, North Tehran Branch, Tehran, Iran.
² Department of Biology, Islamic Azad University, Tonekabon Branch, Mazandran, Iran.
³ Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
⁴ Department of Genetics, Faculty of Basic Sciences, Islamic Azad University, Tehran, Iran.
⁵ Protein Engineering Laboratory, Department of Medical Genetics, School of Medicine, Shahid Sadoughi University of Medical Science, Yazd, Iran.
⁶ Department of Earth and Planetary Sciences, University of Tennessee, Knoxville, USA.
⁷ Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: Movafagh.a@sbmu.ac.ir.
⁸ Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: mosenaghaei123@gmail.com.

PMID: 35690269
DOI: 10.1016/j.diabres.2022.109945

Abstract

Diabetes mellitus (DM) has been the most prevalent global metabolic disease, turning into a serious risk for human health. Several researches have recorded a role for inflammation and immunity in the pathogenesis of both in T1DM and in T2DM. Lots of chemical agents are available to control and to cure diabetic patients, which are not always sufficient for euglycemia maintenance and late stage diabetic complications avoidance. Therefore, newborn therapeutic methods to refine clinical outcomes in DM are required. Nucleic-acid-based therapy also known as gene expression level regulator within the target cells has been calculated to be promising in various diseases. Thus, pronounced attempts have been dedicated to develop new targeted molecular therapy aimed at improving insulin resistance in DM. This review mainly focuses on recent progress in DM molecular therapy and whether, has potential efficacy against inflammatory mediators involved in DM.

Keywords: Diabetes Mellitus; Inflammatory factors; Molecular Therapy.

Publication types

Review

MeSH terms

Diabetes Mellitus, Type 1* / complications
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Diabetes Mellitus, Type 2* / genetics
Humans
Infant, Newborn
Inflammation / complications
Insulin Resistance*